Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083483 | 0.89 | PIK3CA (0.48) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4484215 | 0.88 | MAPK1 (0.44) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4480244 | 0.86 | JMJD6 (0.43) | PIK3CAPIK3CG | |
| SCHEMBL4479863 | 0.81 | MAPK1 (0.39) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4501593 | 0.81 | — | — | |
| SCHEMBL4074400 | 0.78 | MAPK1 (0.46) | MAPK1AURKBABL1PIM1YES1 | |
| SCHEMBL4074131 | 0.78 | — | — | |
| SCHEMBL4080052 | 0.75 | — | — | |
| SCHEMBL4081392 | 0.75 | PIK3CA (0.41) | PIK3CAPIK3CG | |
| SCHEMBL4077505 | 0.74 | ABL1 (0.46) | PIK3CAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| EP-1737459-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1737459-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005089763-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191394-A1 | Antibacterial agents | MRPL21, RPN2, FBL | PIK3CA 2089/4885MAPK8 2827/4885MAPK9 1738/4885 |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DPYD, TYMP, ITPA | PIK3CA 701/4885MAPK8 2259/4885MAPK9 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.